Is sleep disruption a risk factor for Alzheimer’s disease? by Macedo, Arthur Cassa et al.
Manuscript number: 16-1287R2 
 
 
1 
 
 
Is sleep disruption a risk factor for Alzheimer’s disease? 
Arthur Cassa Macedoa, Sara Balouchb and Naji Tabetb 
 
 
Author Note 
aUniversity of Sussex, Brighton, England, UK. 
bCentre for Dementia Studies, Brighton & Sussex Medical School, Brighton, England, UK. 
 
Correspondence concerning this article should be addressed to Dr Sara Balouch, 
Room 101, Trafford Centre for Medical Research, Brighton & Sussex Medical School, 
University of Sussex Campus, Falmer, Brighton, East Sussex, BN1 9RY; Tel +44-1273-
872691; Email: s.balouch@bsms.ac.uk 
 
 
Abstract word count: 246 
Manuscript word count: 3488 
 
 
 
 
RUNNING TITLE: Sleep and Alzheimer’s disease 
Manuscript number: 16-1287R2 
 
 
2 
Abstract 
Sleep disturbances are routinely encountered in Alzheimer’s disease (AD) and affect about 25-
40% of patients in the mild-to-moderate stages of the disease.  In many, sleep pathology may 
represent a symptom of the underlying neurodegeneration.  However, a history of sleep 
disruption occurring years prior to onset of cognitive symptoms could represent a potential risk 
factor for AD.  The aim of the present narrative review was to evaluate current evidence linking 
sleep disturbances with AD development and to understand the mechanisms that may 
contribute to this.  
Although the mechanisms by which poor sleep may contribute to AD genesis is not 
fully understood, emerging evidence linking disturbances in the sleep wake cycle with Aβ 
deposition is shedding light on the relationship between sleep pathology and the subsequent 
development of AD.  Aβ burden appears to be enhanced by sleep-wake cycle disruptions and 
is suspected as being an important mechanism by which sleep disruptions contribute in AD 
development.  Other mechanisms triggered by sleep disruption may also be involved in AD 
development, such as brain hypoxia, oxidative stress, circadian activity rhythms disturbances, 
overexpression of orexins and blood brain barrier impairment.  Further understanding of the 
link between sleep disturbances and future development of AD is still needed before sleep 
disturbances are clearly marked as a preventable risk factor for AD.  In these circumstances, 
early lifestyle interventions to help increase the quantity and quality of sleep may have a 
favorable outcome on decreasing the incidence of AD and this needs to be investigated further.  
 
Keywords: Alzheimer Disease; Dementia; Sleep; Sleep wake disorders; Risk factors. 
 
 
 
Manuscript number: 16-1287R2 
 
 
3 
Introduction 
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by progressive 
cognitive impairment [1] and considered the main cause of dementia, accounting for up to 70% 
of cases [2].  In 2010, the number of people affected by dementia worldwide was estimated to 
be 35.6 million, and this figure is expected to double every 20 years [3]. The increasing number 
of cases, closely related to the increase in human life expectancy, and the absence of a cure for 
AD turns this disease into a major global health problem.  
 The main pathological hallmarks of AD are the diffuse deposition of extracellular 
amyloid-β (Aβ) plaques across the brain parenchyma, the aggregation of hyperphosphorylated 
tau protein into intracellular neurofibrillary tangles (NFT) and neuronal loss [4-6]. The 
accumulation of results from an imbalance between its production and clearance, which is a 
key early step in the pathogenesis of AD and begins 10-20 years before the appearance of 
cognitive symptoms – this period is known as the preclinical stage of AD [7].  
Risk factors for AD include advanced age [8-10], inherited genetic mutations in three 
genes (AβPP, PSEN1 and PSEN2) [11-13], allele apolipoprotein E (APOE) ε4 [14-16], lack of 
aerobic cardiovascular exercise [17], high blood pressure [18], tobacco use [19] and 
hypercholesterolemia [20], among others.  Recently, growing evidence suggests that sleep 
disruption could also be a risk factor for AD.  The focus of this narrative review is to highlight 
the evidence for sleep disruption as a possible risk factor for AD and describe the various 
physiological pathways on how sleep disruption could lead to AD. 
 
Sleep Disturbance as a Characteristic of AD  
Sleep disturbances are routinely encountered in patients with AD and affect 25-40% of 
the patients presenting with mild-to-moderate stages [21].  Several sleep disorders commonly 
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affect AD patients and these include insomnia, diminished duration of night-time sleep, 
increased nocturnal awakenings and enhanced daytime sleep [22].  AD patients also present 
with changes in their sleep architecture that include reduced duration of rapid eye movement 
(REM) sleep stage bouts [23, 24], enhanced duration of stage N1 of non-REM sleep and 
decreased K complexes and sleep spindles [2]. 
 
Associations between Sleep Disruption and AD 
Sleep disturbance in AD may represent a symptom of the progressing underlying 
neurodegeneration.  However, the association between AD and sleep disturbances also raises 
questions about a possible causal role for sleep impairment in AD pathogenesis.  In essence, 
sleep impairment may represent a risk factor for the disease.  In support of this hypothesis, 
studies show that both self-reported sleep problems [25-27] and rest fragmentation at night [28] 
increase the risk of developing dementia, including dementia caused by AD. 
A cross-sectional study conducted by Spira et al. studied 70 community-dwelling 
subjects using self-report sleep measures and [11C]-Pittsburgh compound B positron emission 
tomography (PiB PET) amyloid imaging [29].  They found a greater Aβ burden associated with 
both self-reported shorter sleep duration and poorer sleep quality [29].  Mander et al. [30] also 
used PiB PET to image brain Aβ deposits in 98 older adults.  They compared the amyloid 
burden with sleep scores obtained from both the Epworth Sleepiness Scale (ESS) and the 
Medical Outcomes Study (MOS) Sleep Scale. Greater amyloid deposition in brain regions 
typically affected in AD was associated with self-report of less adequate sleep, more sleep 
problems and greater somnolence. 
Another cross-sectional study of 142 cognitively normal middle-aged and older adults 
showed that lower CSF Aβ42 levels, which indicate greater Aβ deposition, were associated with 
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poorer actigraphic measured sleep efficiency and higher frequency of waking episodes after 
sleep onset (WASO) [31].  However, despite evidence from these cross-sectional studies, it 
remains difficult to infer with certainty that poor sleep is a contributor to AD pathogenesis.  
Notwithstanding this difficulty, the reported association between Aβ deposition and sleep 
disturbances prior to development of AD is of note and may shed light on possible mechanistic 
role for sleep dysfunction as a risk factor for AD. 
Prospective studies also demonstrate associations between several aspects of sleep and 
AD.  Hahn et al. [25], for example, conducted a study with 214 Swedish participants without 
dementia, aged ≥75 years at baseline and showed that the ones presenting with diminished self-
reported sleep depth or duration were approximately 70-100% more likely to be affected by 
all-cause dementia and AD, measured by clinical evaluation 9 years later [25].  Lim et al. [28] 
showed, in a study with 737 cognitively unimpaired older adults, that significant actigraphic 
sleep fragmentation measured during 10 days was associated with enhanced risk of developing 
AD at 6-year follow-up. 
Sterniczuck et al. [26], on the other hand, developed a “sleep disturbance index” that 
included four variables (sleep medication use, sleeping problems and fatigue in past 6 months, 
and “recent trouble sleeping or a change in pattern”).  Using the index, they studied more than 
17,000 older adults and analyzed its association with the presence of self-reported dementia or 
AD approximately 4 years later. Higher indices were linked to 23% greater odds of dementia 
or AD, even after demographic variables, body mass index, and baseline cognitive performance 
had been accounted for [26]. 
Lim et al., on the other hand, used wrist actigraphy to measure sleep consolidation in 
698 cognitively unimpaired older adults.  People presenting with higher levels of sleep 
fragmentation showed a stronger association of APOE ε4 genotype with cognitive decline, 
post-mortem density of neurofibrillary tangles and incident AD [32].  
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Physiological Pathways of Sleep Disruption Leading to AD 
Aβ levels and the sleep-wake cycle.  Studies so far reveal that Aβ levels in both mice 
[33] and humans [34] fluctuate along the sleep-wake cycle in a diurnal pattern.  Kang et al. 
[33] used in vivo cerebral microdialysis to measure Aβ concentration in the brain interstitial 
fluid (ISF) of mice exposed to a 12h light: 12h dark cycle.  It was demonstrated that the Aβ 
levels present a diurnal oscillation, being higher while the mice were awake (during the dark 
phase) and lower when they were asleep (during the light period) [33].  In animals, the diurnal 
oscillation observed in Aβ is also shown by other substances produced by neurons, such as 
lactate, whose variation is in phase with Aβ levels oscillation [35, 36]. 
Measurements of Aβ levels in the cerebrospinal fluid (CSF) were also assessed in 
humans and corroborated the previous findings, as long as a diurnal variation was also 
observed. However, there was a phase delay of approximately 6 hours most likely due to the 
CSF being collected from the lumbar compartment, thus Aβ from the ISF needs time to reach 
this point [33, 34].  Therefore, it seems that Aβ concentration (both in humans and rats) varies 
within the sleep-wake cycle, and disruption of sleep can affect this fluctuating pattern.  In fact, 
the levels of Aβ can variate up to 30% from the highest to the lowest concentration across the 
day [34].  Findings revealing that a change of 25-40% in Aβ production can either protect or 
accelerate the development of AD [37, 38], suggesting that sleep disruption may potentially 
play an important role in contributing to AD pathogenesis. 
Aβ release is a process regulated by neuronal activity [35, 39, 40]. The enhancement of 
neuronal firing causes the increase in Aβ release and, consequently, concentration in the ISF 
[40, 41].  During the wake and REM sleep phases, the firing frequency of the neurons is high, 
while during the slow wave sleep (SWS), cortical neurons overall activity is decreased [42].  
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Sleep disturbances and Aβ aggregation.  The default mode network (DMN), which 
includes the precuneus, medial prefrontal and lateral parietal brain regions, is sorely affected 
by SWS disruptions.  This network is most active when there is no task being performed.  Due 
to its intense neuronal activity, it is more prone to suffer with amyloid deposition [43], which 
has been confirmed by imaging techniques [35, 44].  Normally, sleep diminishes the activity 
of the components of DMN, as well as the connectivity between them and with other structures 
[45, 46]. On the other hand, poor-quality sleep causes an enhancement in DMN connectivity 
and consecutive activity (when compared to high-quality sleep).  Thus, Aβ release increases 
along with the tendency for Aβ plaque formation [47].  
Sprecher et al. [48] demonstrated the complex relationship between Aβ burden and 
sleep disturbance. They found that β-amyloid deposition within medial prefrontal cortex 
(mPFC) was significantly correlated with the disruption degree in NREM (non-rapid eye 
movement) SWA (slow wave activity) generation. Moreover, reduced NREM SWA is 
associated with the impairment in both overnight memory consolidation and hippocampal-
neocortical memory transformation, which could be a possible indirect mechanism by which 
Aβ burden impairs the memory domain in AD. 
Sleep also appears to play a role in Aβ clearance from the brain. This has only been 
shown in a mouse study, however, where an increase of 60% in the brain extracellular space 
volume and in the volume of extracellular fluid was observed during sleep.  The probable 
mechanism underlying this volume increase is a change in the cell volume of astrocytes, which 
occurs due to an alteration in the adrenergic signaling during sleep [49-52].  The Aβ clearance 
is also known to be two-fold faster during sleep [49], mainly because an acceleration in the 
ISF-to-CSF bulk flow and in the blood brain barrier (BBB) transport [49, 53]. The BBB 
transport can be increased both directly (via upregulation of LRP1, transporter that allows Aβ 
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to pass through the BBB) or indirectly through the increase in glymphatic bulk flow [54-56]. 
Impaired sleep appears to be an important factor for diminished Aβ clearance and, 
consequently, increased Aβ concentrations in the brain, which enhances the tendency of Aβ 
accumulation. 
The above findings are supported by research showing that sleep deprivation causes an 
enhancement in Aβ deposition in the APPSWE and APPSWE/PS1DE9 mouse models that are 
characterized by the development of significant amyloid plaques [33]. On the other hand, 
following the increase in sleep promoted by treatment with the orexin antagonist almorexant, 
an attenuation in Aβ plaque burden was observed [33].  In humans, a study showed that CSF 
Aβ concentration decreases following a night of sleep, while after sleep deprivation, this 
concentration was shown to increase [57].  Additionally, Aβ burden was found to be greater in 
community-based older adults with self-reported inadequate quantity and quality in sleep [29]. 
However, another study showed that the diurnal oscillation in the ISF Aβ levels stopped 
occurring in a given brain region after amyloid plaques become present [36]. But, active 
immunization with Aβ before the formation of amyloid plaques prevented Aβ deposition and 
the lack of diurnal pattern, revealing a causal role of Aβ [36].  The same was found for humans 
with presenilin mutations: those who had no amyloid deposition, according to imaging 
techniques, presented with normal diurnal oscillation in Aβ levels, while those who presented 
with amyloid plaques showed a mitigation in the diurnal pattern of CSF Aβ levels [36]. Thus, 
these data suggest that Aβ aggregation disrupts the sleep-wake cycle and diurnal fluctuation of 
Aβ. In essence, poor sleep can lead to increased Aβ levels and subsequent deposition; 
accumulated Aβ disrupts further normal sleep mechanisms resulting in potential worsening of 
sleep pathology which is routinely encountered in AD patients.   
The lack of diurnal oscillation caused by the accumulation of amyloid plaques may be 
due to sequestration of Aβ in those plaques or to an alteration in the neuronal firing pattern. 
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The sequestration of Aβ by amyloid plaques, mainly of the Aβ42 isoform, results in reduced 
clearance of Aβ, compromising its diurnal oscillation [1].  Furthermore, the disruption of SWS 
caused by sleep disturbances, as mentioned before, leads to a lack of deactivation of the DMN 
and enhancement in CSF Aβ levels during sleep period, when they were supposed to fall, 
counteracting the diurnal variation pattern [46].  
 
Sleep disturbances and the blood brain barrier (BBB).  He et al. [58] conducted a 
study with a mice chronic sleep restriction (CSR) model and showed that CSR decreased 
endothelin-1 and the expression of tight junction proteins. The 2-deoxy-glucose uptake by the 
brain was diminished through a downregulation of the glucosetransporter 1 (GLUT1) 
expression in cerebral microvessels of the BBB.  Additionally, impairment of BBB 
permeability was observed. Endothelial and inducible nitric oxide synthase were also 
decreased, whereas the cyclooxygenase-2 related inflammation increased, reflecting 
endothelial damage. These alterations, combined with comorbid medical conditions, could lead 
to permanent damage to the BBB and contribute to neurodegeneration. 
 
Orexins and Alzheimer’s disease pathology.  Orexins are neuropeptide hormones 
with several central [59] and peripheral roles [60] that have been shown to be involved in Aβ 
dynamics regulation [33].  Orexins play a role in wakefulness maintenance and prevent 
undesirable transitions into sleep [61], as presented by orexin knock-out mice and narcoleptic 
patients [62-66].  In mice, chronic overexpression of orexins led to non-REM sleep 
fragmentation and REM sleep suppression during day time [67].  Additionally, the 
consequences of sleep deprivation and orexin modulation over Aβ pathology have also been 
studied in both wild mice and human APP transgenic mice, whose characteristic is the 
expression of a mutated form of human amyloid precursor protein (hAPP).  The results showed 
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that ISF Aβ concentration was enhanced by chronic sleep deprivation and orexin infusion, 
whereas amyloid plaque deposition was reduced by dual orexin receptor antagonist [33].  
 
Oxidative stress induced by extended wakefulness.  Zhang et al. examined the 
metabolic responses of short and long-term sleep loss over the Locus Ceruleus Neurons (LCn) 
of young adult mice. LCns activity reaches high levels during wakefulness and falls greatly in 
NREM sleep, while during REM sleep it becomes quiescent [68].  Enhanced neuronal activity 
across wakefulness requires an increase in their ATP production and consequently more O2
- 
generation [69]. The nicotinamide adenine dinucleotide-dependent deacetylase sirtuin type 3 
(SirT3) upregulates antioxidant mechanisms to protect neurons against oxidative stress [70, 
71], but Zhang et al.’s findings point to the fact that those mechanisms are effective in short-
term wakefulness.  When wakefulness is extended for many consecutive night shifts, SirT3 
activity diminishes, and oxidative stress is observed. Along with metabolic unbalance, LCn 
degeneration occurs, in part due to apoptosis.  Cumulative loss of LCns could then result of 
recurrent episodes of extended wake and lead to cognitive impairment.  Moreover, LCns 
damage could also accelerate neurodegeneration, as shown in previous studies with animal 
models of AD and PD [72-74]. 
 
Hypoxia induced by sleep disordered breathing (SDB).  Emamian et al. showed, in 
a meta-analysis, that patients with AD present a risk five-fold higher of having obstructive 
sleep apnea (OSA) than cognitively normal individuals of similar age [75].  Additionally, 
Haba-Rubio et al. assessed the sleep and cognitive function of 580 individuals aged >65 years 
using validated questionnaires and polysomnography.  Cognitive impaired individuals were 
shown to present with higher sleepiness scores and more disrupted sleep.  These results were 
associated with the severity of the SDB-induced intermittent hypoxia [76]. 
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OSA is characterized by nocturnal intermittent hypoxemia derived from partial or 
complete upper airway obstruction episodes occurring across sleep [77]. Many studies point 
OSA as a possible reversible cause of dementia [78-80].  Sleep-disordered breathing was 
significantly associated with an earlier age of onset of mild cognitive impairment (MCI – a 
preclinical stage of AD) and AD by a longitudinal cohort study [81].  Additionally, community-
dwelling women affected by OSA were shown to present a higher risk of developing MCI or 
dementia [82].  It has also been demonstrated that OSA is associated with enhanced CSF levels 
of Aβ42 and phosphorylated tau in older adults presenting with the APOε3/3 alleles [83]. 
Bu et al. [84] compared serum Aβ and P-tau 181 levels in OSA patients and individuals 
with simple snoring.  Aβ40, Aβ42 and total Aβ levels were considerably higher in OSA 
patients, whose severity of OSA and the consequent hypoxia was positively correlated with 
those levels. Moreover, they found greater P-tau 181 levels in participants affected by OSA. 
These data suggest that chronic intermittent hypoxia is associated to enhanced Aβ levels. 
 Chronic hypoxia leads to downregulation, in neurons, of the expression of ADAM10, 
a candidate protein for α-secretase which is essential to the processing of APP through the non-
amyloidogenic pathway [85].  On the other hand, the level and activity of β-secretase (BACE-
1), an enzyme that participates of the breakdown of APP through the amyloidogenic pathway, 
are both increased by the upregulation of hypoxia-inducible factor 1α (HIF-1-α) caused by 
hypoxia [86-88].  Additionally, zinc metalloproteinase neprilysin (NEP), an enzyme that 
cleaves Aβ, is downregulated by hypoxia [89].  Taken together, these data suggest that hypoxia 
may enhance Aβ levels by increasing its generation and diminishing its breakdown. 
 Tau-protein hyperphosphorylation was also shown to be induced by hypoxia in mice 
by activating kinases which phosphorylate tau (such as glycogen synthase kinase 3 beta, 
mitogen-activated protein kinase and cyclin-dependent kinase 5) and inactivating the protein 
phosphatase 2A (PPA2), an enzyme that dephosphorylate tau [90, 91].  Furthermore, chronic 
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hypoxia can also accelerate tau pathology via calpain-mediated tau hyperphosphorylation [92, 
93]. 
  
Circadian activity rhythms and risk of Alzheimer’s disease.  Other circadian 
disturbances rather than sleep disruptions were also suggested as a potential risk factor for AD 
development.  AD patients are commonly affected by some circadian disturbances, including 
reduced amplitudes and phase delay of circadian variation in core body temperature and 
activity [94].  Tranah et al. [95] measured circadian activity rhythms by wrist actigraphy in 
1282 healthy community-dwelling older women (mean age 83 years), which were also 
clinically evaluated and classified approximately 5 years later according to their cognitive 
status (normal, MCI, dementia).  They found that circadian activity rhythms were prospectively 
associated with incident dementia or mild cognitive impairment (MCI). Older women 
presenting with diminished activity rhythms were more likely to develop dementia or MCI. 
Lower amplitude, a delayed timing of peak activity and a less robust rhythm showed consistent 
association with development of dementia or MCI, independent of the sleep fragmentation and 
sleep duration.  
Based on these findings, activity rhythm abnormalities could be a prognostic factor of 
enhanced risk for dementia and MCI in older, cognitively healthy community-dwelling 
women. Further studies are necessary to confirm the direct causal relationship between 
circadian rhythm disturbances and MCI/dementia and to establish if interventions that prevent 
circadian rhythm disturbances could delay the onset of MCI/dementia.  Potential interventions 
include physical activity and light exposure [96-102], strengthen circadian activity rhythms, 
and improve sleep synchronization in older adults [102-106].  
 
Sleep Disturbances in other Neurodegenerative Disorders 
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Finally, sleep disturbances are not specific to AD.  There appears to be a two-way 
cause-effect link between sleep disruption and other neurodegenerative disorders too. Sleep 
disturbances are usually found as non-motor manifestations of Parkinson’s Disease (PD) [107].  
Studies suggest that sleep disturbances presented by patients with PD, such as NREM sleep 
irregularities on EEG and sleep spindle alterations correlate with increased risk for developing 
dementia [107, 108].  Additionally, the onset of motor symptoms of Parkinsonism in PD and 
Dementia with Lewy Bodies (DLB) appears to be preceded by REM sleep Behavior Disorder 
(RBD) in many years [109-112].  Eventually, sleep disturbances with nighttime sleep 
disruptions are frequently encountered in DLB [113].  
Patients affected by vascular dementia (VaD), in turn, suffer with sleep-wake cycle 
disruption and diminished sleep efficiency [114].  Furthermore, recent studies indicate that 
sleep disruptions, mainly excessive daytime sleepiness, seem to show a strong correlation with 
higher predictive power for subsequent VaD [115].  Moreover, sleep disturbances characterized 
by enhanced nocturnal activity, excessive daytime sleepiness and reduced morning activity 
have all been reported in patients with Frontotemporal Dementia [109, 116-118].  These 
findings suggest that perhaps sleep disruption is a risk factor for dementia in general and not 
solely Alzheimer-type dementia. 
 
Conclusions 
In this review we have presented evidence that clearly demonstrates how disturbances 
in the sleep cycle may contribute to the etiology of AD through various different physiological 
pathways. This suggests that sleep disturbance is a preventable risk factor for AD.  
Early interventions in patients presenting with disrupted sleep cycles, regardless of the 
cause, are necessary to both improve the quality of life of the individual and to avoid the 
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consequences of a dysregulated sleep, which may include an acceleration of the progression of 
AD (see Ooms and Ju for a review on treatment in dementia [119]).  
The timely management of sleep disorders is an important potential strategy to prevent 
or at least delay the onset of AD.   Although many studies support the relationship between 
sleep impairment and AD pathogenesis, the extent of the role of sleep in the causality of this 
disease is not yet clear.  Further studies are needed to understand fully the correlation between 
sleep disturbances and AD, such as prospective studies using polysomnography - the gold 
standard for the measurement of sleep disturbances.  Prospective studies investigating the 
effects of improving the quality of sleep in AD onset are also necessary to determine the role 
of sleep disturbances in AD onset.  Nevertheless, the association between sleep disturbance 
and Aβ deposition (and possibly tau) provides a credible mechanistic pathway.  Understanding 
the mechanisms that may link a history of sleep impairment with the subsequent development 
of AD will be crucial in helping with prevention. The emerging data about sleep as a potential 
risk factor for AD will highlight the need for future assessment of pharmacological and non-
pharmacological interventions to optimize treatment of sleep disorders specifically in relation 
to AD prevention. 
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